Hematologic Markers as Prognostic Factors in Nonmetastatic Esophageal Cancer Patients under Concurrent Chemoradiotherapy

Abstract EN

Nonmetastatic esophageal cancer can demonstrate a high local recurrence rate even under the standard treatment.

We evaluated platelet counts before and after concurrent chemoradiotherapy (CCRT), neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio for predicting esophageal cancer prognosis under CCRT.

Newly diagnosed patients with esophageal cancer (stages IA–IIIC) who underwent CCRT during January 2013–December 2017 were enrolled.

The data were collected retrospectively.

Overall survival (OS), time to progressive disease (TPD), and time to metastasis (TM) were recorded for indicating prognosis.

Kaplan–Meier curves were plotted and univariate and multivariate analyses were performed.

In total, 105 patients were enrolled.

The stages of esophageal cancer and surgery were associated with prognosis (i.e., OS, TPD, and TM).

Based on TPD and TM, women had better prognosis than men.

In the univariate analysis, high pre- and post-CCRT platelet counts (>300,000/μL), platelet-to-lymphocyte ratio (PLR), and neutrophil-to-lymphocyte ratio (NLR) as well as low lymphocyte percentage were significantly associated with poor prognosis.

However, in the multivariate analysis, only post-CCRT high platelet count (>300,000/μL) remained significantly associated with poor prognosis (P = .041, .045, and .023 for OS, TPD, and TM, respectively).

Poor prognosis was observed in patients with high platelet counts, PLR, NLR, and low lymphocyte percentage.

Surgery was an independent factor predicting better prognosis.

Our findings may have clinical significance with regard to therapeutic decision-making.